Aleva Neurotherapeutics develops implantable deep brain stimulation (DBS) systems designed to improve the precision and therapeutic outcomes of neuromodulation in movement disorders. The company’s platform is based on micro-electromechanical systems (MEMS) technology, enabling highly directional stimulation within deep brain targets. Its implantable hardware is engineered to deliver electrical stimulation with increased spatial control compared to conventional DBS electrodes. Aleva’s systems are intended for chronic implantation in regulated clinical settings.

The technology uses segmented, directional electrodes that allow clinicians to shape stimulation fields within specific neural structures. By steering current toward therapeutic targets and away from surrounding tissue, the system aims to reduce side effects while preserving clinical efficacy. The platform integrates with programmable implantable pulse generators, allowing post-implantation adjustment of stimulation parameters. This approach supports more personalized neuromodulation based on patient anatomy and response.

Aleva Neurotherapeutics positions its DBS technology for the treatment of Parkinson’s disease and essential tremor within established neurosurgical and neurological care pathways. The system is designed for use by clinicians in specialized centers and aligns with existing DBS workflows and regulatory frameworks. Its primary value proposition lies in improving targeting precision and clinical flexibility for patients requiring long-term neuromodulation therapy.